Market Surveillance Authorities & Customs Sample Clauses

Market Surveillance Authorities & Customs. Customs checklists should be easy to understand and simple to use. As a preliminary investigation by customs officers or even market surveillance officers during inspections at outlets, it may be worth taking a quick look at product labelling / instructions in order to see what standard they refers to. The products with no label whatsoever were found to have almost a 100% chance of having some form of non- compliance. Additionally, from the samples checked and tested, 67% were found to have a serious risk. This therefore could possibly be a good preliminary indicator that something might not be right with the respective product. With regard to developing checklists for customs, it is important to identify clear and simple and indicators for when to “raise a flag” and inform the market surveillance authorities that further investigations are required on the product rather than making the customs officers experts on the products. In the last CCA meeting held in December 2013, Customs checklists were drafted. These were made specifically with the intention that they should be very easy to understand and simple to go through. These checklists will eventually be handed over, in coordination with PROSAFE, to the Customs-Market Surveillance Working Group. This Group is coordinated by DG-TAXUD, and they have already developed a number of product safety checklists on a various number of product groups. The CCA working group has also learnt some lessons which might be useful to market surveillance authorities and future joint market surveillance activities across Europe. Checklists were found to be useful in assisting the respective inspectors on checking and investigating a number of samples which could eventually be acquired for testing purposes. The checklists ensured that market surveillance inspectors were able to perform adequate preliminary investigations before choosing a particular sample for testing. Tendering for the testing of products at European level was found to be very useful. It not only ensured that all tests were carried out by one laboratory but the economies of scale also ensured that the prices quoted by the laboratories were much more competitive due to the high number of samples to be tested. This usually resulted in the laboratory being able to perform additional tests for the same amount of budget, thereby ensuring efficiency amongst market surveillance authorities across Europe. It is also important to set up communication- and timeframe ...
Sample 1
AutoNDA by SimpleDocs
Market Surveillance Authorities & Customs. The CCA working group learnt some lessons which might be useful to market surveillance authorities and future joint market surveillance activities across Europe. When it comes to the checking of product information at European level, it was found to be very difficult to do this via checklists. It is therefore strongly recommended that future joint actions should ensure that all such information is checked directly by one source, ideally, the laboratory itself where the testing will be done. This will ensure that all checklists are checked independently and also by the same entity, providing results which may be much more reliable in the long run. Tendering for the testing of products at European level has been found to be very useful. It not only ensures that all tests are mainly done by one laboratory but economies of scale will also ensure that the prices quoted by the laboratories, due to the higher number of samples tested, will be much more competitive. This usually results in laboratories being able to perform additional tests for the same amount of budget, thus ensuring efficiency amongst market surveillance authorities across Europe. Checklists were found to be useful in assisting the respective inspectors in checking and investigating a number of samples which could eventually be acquired for testing purposes. This ensured that market surveillance inspectors were able to perform adequate preliminary investigations before choosing a particular sample for testing. During the last CCA meeting held in December 2013, Customs checklists were drafted. This was done specifically with the intention that they should be very easy to understand and simple to go through. These checklists will be eventually be handed over to the Customs-Market Surveillance Working Group coordinated by DG-TAXUD which has already developed a number of product safety checklists on a various number of product groups. One last point worth noting is that some market surveillance authorities, such as the Swedish Consumer Agency, have in fact published brochures on the risks found in childcare articles, mainly targeting parents and carers. The brochures are in various languages to ensure that they reach all parents / carers within Sweden and are also available on the website. A copy of one of these brochures is shown in Annex 1 of this document. Market surveillance authorities may consider developing brochures similar to the one shown in Annex 1 or provide information within their own ...
Sample 1

Related to Market Surveillance Authorities & Customs

  • Video Surveillance All video surveillance will be directed by the YSU police department.

  • Surveillance The COR will receive and document all complaints from Government personnel regarding the services provided. If appropriate, the COR will send the complaints to the Contractor for corrective action.

  • Regulatory Reporting Ultimus agrees to provide reports to the federal and applicable state authorities, including the SEC, and to the Funds’ Auditors. Applicable state authorities are those governmental agencies located in states in which the Fund is registered to sell shares.

  • Cooperation with Authorities Each party hereto shall cooperate with the other party and all appropriate governmental authorities (including without limitation the SEC) and shall permit such authorities reasonable access to its books and records in connection with any investigation or inquiry relating to this agreement or the transactions contemplated hereby.

  • Procurement procedures 11.1 The Recipient must secure the best value for money and shall act in a fair, open and non-discriminatory manner in all purchases of goods and services.

  • Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package or the Prospectus, each of the Company and its subsidiaries: (a) is and at all times has been in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company (“Applicable Laws”); (b) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other federal, state or foreign governmental authority having authority over the Company (“Governmental Authority”) alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (c) possesses all Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (d) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority or third party alleging that any product, operation or activity is in violation of any Applicable Laws or Authorizations and have no knowledge that any such Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (e) has not received notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Authority is considering such action; and (f) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission). The studies, tests and preclinical and clinical trials material to the Company and its subsidiaries taken as a whole, and conducted by or on behalf of the Company and each of its subsidiaries, were and, if still pending, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws and Authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package or the Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, the Company is not aware of any studies, tests or trials the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus when viewed in the context in which such results are described and the clinical state of development; and neither the Company nor any of its subsidiaries has received any notices or correspondence from any Governmental Authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are material to the Company and its subsidiaries taken as a whole.

  • Department of Transportation Bridge Maintenance employees, when actually climbing the cable stays of the Penobscot Narrows Bridge for inspection and/or repair, shall be compensated at the rate of ten dollars ($10.00) an hour in addition to their regular hourly rate of pay. Employees shall be compensated for a minimum of one (1) hour of such work regardless of the length of the climbing assignment.

  • Regulatory Reports Since January 1, 2018, Company and its Subsidiaries have duly filed with the FRB, the FDIC, the OCC and any other applicable Governmental Authority, in correct form, the reports and other documents required to be filed under applicable Laws and regulations and have paid all fees and assessments due and payable in connection therewith, and such reports were, in all material respects, complete and accurate and in compliance with the requirements of applicable Laws and regulations. No report, including any report filed with the OCC, the FDIC, the Federal Reserve Board, the Securities Exchange Commission or any other federal or state regulatory agency, and no report, proxy statement, registration statement or offering materials made or given to shareholders of Company or the Bank, in each case, since December 31, 2017, as of the respective dates thereof, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The call reports of the Bank and accompanying schedules as filed with the OCC, for each calendar quarter beginning with the quarter ended December 31, 2017, through the Closing Date have been and will be prepared in accordance with applicable regulatory requirements, including applicable regulatory accounting principles and practices through periods covered by such reports. Other than normal examinations conducted by a Governmental Authority in the Ordinary Course of Business of Company and its Subsidiaries, no Governmental Authority has notified Company or any of its Subsidiaries that it has initiated or has pending any proceeding or, to Company’s Knowledge, threatened an investigation into the business or operations of Company or any of its Subsidiaries since January 1, 2018 that would reasonably be expected to result in a Material Adverse Effect on Company. There is no material unresolved violation, criticism, or exception by any Governmental Authority with respect to any report or statement relating to any examinations or inspections of Company or any of its Subsidiaries. There have been no formal or informal inquiries by, or disagreements or disputes with, any Governmental Authority with respect to the business, operations, policies or procedures of Company or any of its Subsidiaries since January 1, 2018. Notwithstanding the foregoing, nothing in this Section 3.09 shall require Company or Bank to provide Buyer with any confidential regulatory supervisory information of Company or Bank.

  • REGULATORY ADMINISTRATION SERVICES BNY Mellon shall provide the following regulatory administration services for each Fund and Series:  Assist the Fund in responding to SEC examination requests by providing requested documents in the possession of BNY Mellon that are on the SEC examination request list and by making employees responsible for providing services available to regulatory authorities having jurisdiction over the performance of such services as may be required or reasonably requested by such regulatory authorities;  Assist with and/or coordinate such other filings, notices and regulatory matters and other due diligence requests or requests for proposal on such terms and conditions as BNY Mellon and the applicable Fund on behalf of itself and its Series may mutually agree upon in writing from time to time; and

  • Security Controls for State Agency Data In accordance with Senate Bill 475, Acts 2021, 87th Leg., R.S., pursuant to Texas Government Code, Section 2054.138, Contractor understands, acknowledges, and agrees that if, pursuant to this Contract, Contractor is or will be authorized to access, transmit, use, or store data for System Agency, Contractor is required to meet the security controls the System Agency determines are proportionate with System Agency’s risk under the Contract based on the sensitivity of System Agency’s data and that Contractor must periodically provide to System Agency evidence that Contractor meets the security controls required under the Contract.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!